Literature DB >> 15193997

Increased chloride efflux in colchicine-resistant airway epithelial cell lines.

Anca Dragomir1, Godfried M Roomans.   

Abstract

Colchicine has been proposed as a treatment to alleviate chronic lung inflammation in cystic fibrosis patients and clinical trials are ongoing. Our aim was to investigate whether chronic exposure of cystic fibrosis cells to colchicine can affect their ability to transport chloride in response to cAMP. Colchicine-resistant cells were selected by growing in medium containing nanomolar concentrations of the drug. While microtubuli were affected by acute exposure to colchicine, they appeared normal in colchicine-resistant cells. Colchicine-resistant clones had higher expression of multidrug resistance proteins compared to untreated cells. Cystic fibrosis transmembrane conductance regulator (CFTR) labelling by immunocytochemistry showed no significant changes. The intracellular chloride concentration and basal chloride efflux of the cystic fibrosis treated cells increased significantly compared with untreated cells, while for the cAMP-stimulated Cl-efflux there was no significant change. The results suggest that colchicine promotes chloride efflux via alternative chloride channels. Since this is an accepted strategy for pharmacological treatment of cystic fibrosis, the results strengthen the notion that colchicine would be beneficial to these patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193997     DOI: 10.1016/j.bcp.2004.03.037

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  3 in total

1.  Expression and function of NFAT5 in medullary thick ascending limb (mTAL) cells.

Authors:  Shoujin Hao; Hong Zhao; Zbigniew Darzynkiewicz; Sailaja Battula; Nicholas R Ferreri
Journal:  Am J Physiol Renal Physiol       Date:  2009-04-15

2.  ClC-7/Ostm1 contribute to the ability of tea polyphenols to maintain bone homeostasis in C57BL/6 mice, protecting against fluorosis.

Authors:  Bing-Yun Li; Yan-Hui Gao; Jun-Rui Pei; Yan-Mei Yang; Wei Zhang; Dian-Jun Sun
Journal:  Int J Mol Med       Date:  2017-03-22       Impact factor: 4.101

3.  Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers.

Authors:  O B Garbuzenko; N Kbah; A Kuzmov; N Pogrebnyak; V Pozharov; T Minko
Journal:  J Control Release       Date:  2019-01-21       Impact factor: 9.776

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.